Researchers conducted a small Phase II study to test a combination treatment for advanced non-small cell lung cancer. The study included 30 patients with Stage IIIA-IIIC disease who had refused or were ineligible for standard treatments like chemotherapy or radiation. They received bronchial arterial chemoembolization (a procedure that delivers chemotherapy directly to lung tumors) followed by tislelizumab, an immunotherapy drug given every three weeks.
The study found that patients had a median progression-free survival of 10.5 months (meaning half of patients lived without their cancer worsening for at least that long) and a median overall survival of 15.0 months. About 60% of patients had their tumors shrink significantly, and 80% had their disease controlled. Quality of life measures improved after treatment. Safety was acceptable, with no severe treatment-related side effects reported.
It's important to understand this was an early, exploratory study without a comparison group. Because there was no group receiving standard treatment or placebo, we cannot say if this combination works better than existing options. The small size (30 patients) and single-arm design mean results should be interpreted cautiously.
This research provides preliminary evidence that this combination approach might help patients who cannot receive standard treatments, but it does not change current medical practice. The findings support conducting larger, randomized trials to compare this approach against standard care.
